Merck Just Got Two FDA Approvals in Two Days. The Market Hasn't Fully Noticed Yet.

Signal: BUY | Score: 48.63/100

Merck dropped back-to-back FDA approvals this week and analysts have been raising targets since early September. At $148.55, MRK is sitting less than 6% below its 52-week high with fresh catalysts, a 2.3% dividend, and earnings in 34 days. This setup has more going for it than most people realize.

The Setup

MRK has had a remarkable run off its 52-week low of $77.69, nearly doubling to where it trades today. The RSI sits at 57.5 - healthy momentum without being overbought. The stock is consolidating just below the $156.92 high, which is classic pre-breakout behavior. With a beta of just 0.23, this is not a wild ride - it's a steady compounder building pressure before the next leg up. The technical score of 57.97 and momentum score of 56.25 both confirm the trend is intact and pointing higher.

The Catalyst

This is where it gets interesting. Merck just had one of the busiest two-day regulatory stretches of the year.

On September 24th, the FDA expanded the WINREVAIR label to include Phase 3 HYPERION data for newly diagnosed PAH patients. That's not a minor tweak - it opens the commercial opportunity significantly for Merck's cardiovascular franchise.

Then on September 25th - today - the FDA approved WELIREG plus LENVIMA for previously treated advanced clear-cell renal cell carcinoma. Two oncology drugs, one combo approval, bigger addressable market.

Layer on top of that: Guggenheim raised its price target to $170 on September 8th, Wall Street Zen upgraded to Buy on September 20th, and Merck reported $16.61 billion in quarterly revenue with earnings above expectations. The analyst consensus sits at a "Moderate Buy" with a $153.65 target. That's before the market fully prices in this week's catalysts.

Bull Case

Guggenheim's $170 target implies 14.5% upside from here, and that was set before this week's approvals
Earnings on October 29th give the stock a natural catalyst runway - the next 34 days are a setup window
Forward PE of 15.6x tells you the market is pricing in real earnings growth, not just hope - this is a value play hiding inside a large-cap healthcare name

Bear Case

Trailing PE of 118x and a profit margin of just 4.8% show Keytruda dependency is still a real overhang. Any pipeline setback hits hard.
Debt-to-equity of 128x is elevated. Rising rates or credit tightening could pressure the balance sheet narrative.

The Trade

Entry: $148.55
Target: $165 (just below Guggenheim's $170 target, gives breathing room)
Stop Loss: $138 (roughly 7% downside, below key support)
Risk/Reward: approximately 1:1.6
Timeframe: 6 to 10 weeks, through earnings on October 29th

*This is one person's analysis, not financial advice. Always do your own research.*